scios
said
suspended
development
auriculin
anaritide
based
results
interim
analysis
data
phase
iii
study
oliguric
acute
renal
failure.the
study
suspended
low
probability
positive
outcome
obtained
respect
primary
clinical
endpoint
dialysis
free
survival.despite
development
remain
optimistic
viability
products
pipeline
company
said
